Evidence map›Paper›PMID 33141894›Full record

ArticleSchizophrenia bulletin2021

Comprehensive Gene Expression Analysis Detects Global Reduction of Proteasome Subunits in Schizophrenia.

Libi Hertzberg, Nicola Maggio, Inna Muler, Assif Yitzhaky, Michael Majer, Vahram Haroutunian, Or Zuk, Pavel Katsel, Eytan Domany, Mark Weiser

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Schizophrenia bulletin, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Blood T Helper Memory Cells: A Tool for Studying Skin Inflammation in HS?International journal of molecular sciences · 2023
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Libi HertzbergDepartment of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel.
Nicola MaggioDepartment of Neurology, The Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Inna MulerChildhood Leukemia Research Institute and the Department of Pediatric Hemato-Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Assif YitzhakyDepartment of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel.
Michael MajerDepartment of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel.
Vahram HaroutunianDepartments of Psychiatry and Neuroscience, The Mount Sinai School of Medicine, New York, NY.
Or ZukDepartment of Statistics, The Hebrew University of Jerusalem, Jerusalem, Israel.
Pavel KatselDepartments of Psychiatry and Neuroscience, The Mount Sinai School of Medicine, New York, NY.
Eytan DomanyDepartment of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel.
Mark WeiserDepartment of Psychiatry, Chaim Sheba Medical Center, Ramat-Gan and the Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Tel Aviv University · ILWeizmann Institute of Science · ILHebrew University of Jerusalem · ILIcahn School of Medicine at Mount Sinai · USJames J. Peters VA Medical Center · US

Funding

NIDA NIH HHS HHSN271201300031C
6 · The paper itself

Abstract

backgroundThe main challenge in the study of schizophrenia is its high heterogeneity. While it is generally accepted that there exist several biological mechanisms that may define distinct schizophrenia subtypes, they have not been identified yet. We performed comprehensive gene expression analysis to search for molecular signals that differentiate schizophrenia patients from healthy controls and examined whether an identified signal was concentrated in a subgroup of the patients.

methodsTranscriptome sequencing of 14 superior temporal gyrus (STG) samples of subjects with schizophrenia and 15 matched controls from the Stanley Medical Research Institute (SMRI) was performed. Differential expression and pathway enrichment analysis results were compared to an independent cohort. Replicability was tested on 6 additional independent datasets.

resultsThe 2 STG cohorts showed high replicability. Pathway enrichment analysis of the down-regulated genes pointed to proteasome-related pathways. Meta-analysis of differential expression identified down-regulation of 12 of 39 proteasome subunit genes in schizophrenia. The signal of proteasome subunits down-regulation was replicated in 6 additional datasets (overall 8 cohorts with 267 schizophrenia and 266 control samples, from 5 brain regions). The signal was concentrated in a subgroup of patients with schizophrenia.

conclusionsWe detected global down-regulation of proteasome subunits in a subgroup of patients with schizophrenia. We hypothesize that the down-regulation of proteasome subunits leads to proteasome dysfunction that causes accumulation of ubiquitinated proteins, which has been recently detected in a subgroup of schizophrenia patients. Thus, down-regulation of proteasome subunits might define a biological subtype of schizophrenia.

Indexed as

Gene Expression ProfilingTranscriptomeAdultAgedAged, 80 and overBrainDatasets as TopicDiagnosisDown-RegulationFemaleHumansMaleMiddle AgedProteasome Endopeptidase ComplexSchizophreniaTemporal LobeProteasome Endopeptidase Complexgene expressionintegrated analysispostmortem brain samplesubiquitin proteasome system

Identifiers

PMID33141894
PMCPMC8084431
OpenAlexW3095081207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.